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The MMSET (Multiple Myeloma SET domain) protein is
overexpressed in multiple myeloma patients harboring the
translocation t(4;14), and is believed to be the driving factor
in the pathogenesis of this subtype of myeloma. Our stu-
dies showed that overexpression of MMSET in myeloma
cells induces a global increase in H3K36 dimethylation, a
mark associated with actively transcribed genes, and a con-
comitant genome-wide loss of H3K27 trimethylation. This
effect is due to an enhanced rate of H3K36 methylation as
well as an increased rate of H3K27 demethylation leading
to altered gene expression. Using ChIP-Seq and genetically
matched cells in which the overexpressed MMSET allele
was knocked out (KMS11-TKO), we found that increased
H3K36 methylation due to MMSET disrupts the normal
genomic H3K36me2 architecture, from a mostly promo-
ter-enriched mark to a modification spread throughout
the genome. Additionally, many loci activated in response
to MMSET showed the loss of H3K27 methylation near
the transcriptional start site. Surprisingly, while MMSET-
overexpressing cells lose the H3K27me3 mark globally,
specific loci display enrichment of this modification and
are transcriptionally repressed. This is associated with a
shift in the genomic localization of the H3K27 methyl-
transferase, EZH2, in the presence of MMSET. Thus, in
addition to gene activation through increased H3K36
methylation, overexpression of MMSET can also induce
gene repression by imposing EZH2 and H3K27me3 accu-
mulation at specific genomic loci.
Using KMS11-TKO cells, we performed a structure-
function study to identify important domains of
MMSET. Re-introduction of the wild-type MMSET into
the TKO cells induces the H3K36/H3K27 epigenetic
switch, enhances proliferation and colony formation of
these cells, and leads to differential gene expression.
These biological activities require all four PHD finger
domains, the second PWWP domain and the functional
SET domain. When MMSET constructs containing
mutations or deletions in one of these domains were
overexpressed in TKO cells, the resulting protein failed
to methylate histones, alter growth or change gene
expression. Furthermore, point mutations in the PHD
domains 2 or 3 prevented MMSET from binding to chro-
matin and altering histone methylation. By contrast, an
MMSET construct lacking the C-terminal PHD4 domain
bound chromatin, induced methylation of H3K36, but
was unable to mediate a complete loss of the H3K27me3
mark or fully stimulate growth. Together this suggests
that pathogenic activity of MMSET could be interrupted
by blocking its binding to chromatin, its intrinsic H3K36
methylation activity or by blocking demethylases of
H3K27 that might interact with MMSET.
To validate MMSET as a therapeutic target, we used
KMS11 t(4;14)+ cells that express MMSET specific
shRNA in the presence of doxycycline. KMS11 cells
rapidly formed tumors when injected into immunocom-
promised mice. Doxycycline treatment caused a dramatic
decrease in the volume of established tumors, extended
survival in mice and, in some cases, completely eliminated
the tumor burden. Together, our work elucidates some of
the mechanisms used by MMSET to induce an oncogenic
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phenotype and identifies domains to be considered in
designing novel inhibitors of MMSET function.
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